RCM
FULC icon

RA Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

RA Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.4M Hold
6,053,960
– – 0.49% 37
2025
Q4 		$68.5M Sell
6,053,960
-4,175,139
-41% -$42.5M 0.7% 28
2025
Q3 		$94.1M Hold
10,229,099
– – 1.16% 24
2025
Q2 		$70.4M Hold
10,229,099
– – 1.19% 22
2025
Q1 		$29.5M Hold
10,229,099
– – 0.49% 32
2024
Q4 		$48.1M Hold
10,229,099
– – 0.64% 32
2024
Q3 		$36.5M Sell
10,229,099
-1,380,605
-12% -$10.2M 0.42% 46
2024
Q2 		$72M Hold
11,609,704
– – 0.95% 31
2024
Q1 		$110M Hold
11,609,704
– – 1.39% 23
2023
Q4 		$78.4M Hold
11,609,704
– – 1.22% 25
2023
Q3 		$51.5M Hold
11,609,704
– – 1.01% 29
2023
Q2 		$38.3M Hold
11,609,704
– – 0.72% 37
2023
Q1 		$33.1M Buy
11,609,704
+2,103,779
+22% +$18.8M 0.75% 40
2022
Q4 		$69.2M Buy
9,505,925
+2,505,925
+36% +$16.3M 1.4% 25
2022
Q3 		$56.6M Buy
+7,000,000
New +$50.1M 1.21% 31

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RA Capital Management's FULC Position: Q1 2026 in Review

RA Capital Management held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 6,053,960 shares worth $46.4M. The position accounts for 0.49% of the portfolio, ranked #37.

RA Capital Management first reported a position in FULC in Q3 2022 and has held it in 15 quarters since. The position peaked at $110M in Q1 2024. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • RA Capital Management held 6,053,960 shares of Fulcrum Therapeutics worth $46.4M as of Q1 2026.
  • RA Capital Management left its Fulcrum Therapeutics share count unchanged in Q1 2026.
  • Fulcrum Therapeutics made up 0.49% of RA Capital Management's portfolio in Q1 2026, its #37 holding.
  • RA Capital Management first reported a position in Fulcrum Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • RA Capital Management's Fulcrum Therapeutics position peaked at $110M in Q1 2024.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.